Enhanced Composition for Obesity and Lipid-Related Metabolic Disorders
Legal Citation
Summary of the Inventive Concept
The present invention relates to novel compositions and methods for preventing or treating obesity and lipid-related metabolic disorders, offering improved efficacy, safety, and personalized treatment options.
Background and Problem Solved
The original patent disclosed a composition for preventing or treating obesity or lipid-related metabolic disorders, but it had limitations in terms of efficacy, side effects, and individual responsiveness. The present inventive concept addresses these limitations by introducing synergistic combinations of steroid sulfatase inhibitors and lipase inhibitors, polyunsaturated fatty acids, and genetic testing modules to enhance weight loss, lipid metabolism, and personalized treatment.
Detailed Description of the Inventive Concept
The inventive concept comprises a system for preventing or treating obesity or lipid-related metabolic disorders, featuring a steroid sulfatase inhibitor and a lipase inhibitor administered in a synergistic ratio to enhance weight loss and lipid metabolism. Additionally, the invention encompasses methods for enhancing the efficacy of a steroid sulfatase inhibitor, compositions comprising a steroid sulfatase inhibitor and a polyunsaturated fatty acid, and systems for personalized treatment incorporating genetic testing modules. These novel combinations and methods overcome the limitations of the original patent, providing improved therapeutic outcomes and reduced side effects.
Novelty and Inventive Step
The new claims introduce novel synergistic combinations of steroid sulfatase inhibitors and lipase inhibitors, as well as the use of polyunsaturated fatty acids and genetic testing modules, which are not obvious from the original patent. These innovations provide a significant improvement over the prior art, enabling more effective and personalized treatment of obesity and lipid-related metabolic disorders.
Alternative Embodiments and Variations
Alternative embodiments of the inventive concept may include varying the ratio of steroid sulfatase inhibitors to lipase inhibitors, using different polyunsaturated fatty acids, or incorporating additional therapeutic agents. Furthermore, the genetic testing module could be adapted for use with different genetic markers or biomarkers, expanding the scope of personalized treatment options.
Potential Commercial Applications and Market
The inventive concept has significant commercial potential in the pharmaceutical and healthcare industries, particularly in the areas of obesity and lipid-related metabolic disorders. The improved efficacy, safety, and personalized treatment options offered by this invention could lead to a substantial market share and revenue growth.
Section 103 Obviousness Analysis (PHOSITA)
Field of Art
Pharmaceutical composition design for metabolic disorders, specifically focusing on obesity treatment and lipid metabolism interventions, requiring expertise in pharmacology, biochemistry, and drug formulation
Person of Ordinary Skill (PHOSITA) Profile
A pharmaceutical researcher with advanced degree in pharmacology or biochemistry, familiar with steroid sulfatase inhibitors, lipid metabolism mechanisms, and drug combination strategies, possessing knowledge of metabolic disorder treatment approaches
Obviousness Rationale
A person skilled in the art would recognize that combining steroid sulfatase inhibitors with complementary agents like lipase inhibitors or polyunsaturated fatty acids represents a predictable extension of existing obesity treatment strategies. The source patent's focus on metabolic disorder interventions provides a clear motivation for exploring synergistic combinations to enhance therapeutic efficacy. Furthermore, the systematic approach of incorporating genetic testing modules aligns with contemporary personalized medicine trends in pharmaceutical research.
Obvious Combinations & Variations
Original Patent Information
| Patent Number | US 11,857,533 |
|---|---|
| Title | Composition for preventing or treating obesity or lipid-related metabolic disorders |
| Assignee(s) | Nexyon Biotech Co., Ltd. |